Browse EX-10 agreements

Exhibit 10.30b

 

CREDITLINE PROMISSORY NOTE

(Amended and Restated as of June 1, 2026)

 

Dated: June 1, 2026

FOR VALUE RECEIVED, on June 1, 2026, the undersigned Nutriband Inc., 121 South Orange Street, Suite 1500, Orlando, Florida 32801(” Borrower”), promises to pay to the order of TII JET SERVICES,LDA, or order (“Lender”), with offices at Rua das Ladeiras 5, Porto Santo, 9400-131 Portugal, the principal sum of Five Million Dollars ($5,000,000), or so much thereof as is advanced hereunder (“Advances”), with interest at the rate of Seven (7%) Percent per annum. Borrower shall make payments of interest accrued on the outstanding amount of this credit line note (the “Note” or this “Credit Line”) as of each calendar year end during the term of the Credit Line, commencing with June 1, 2026. Such payments of accrued interest shall be paid within 30 days of the respective December 31 accrual amount determination date and shall be accompanied by a Compliance Certificate, properly completed and executed by the Borrower, indicating that the Borrower is in compliance with all cove

…

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

UNSECURED PROMISSORY NOTE

 

$[_____________]

__________, 2026

…

EXCHANGE AGREEMENT

 

THIS EXCHANGE AGREEMENT (this “Agreement”) is made as of June 16, 2026, by and among the undersigned holders (each, a “Holder” and, together, the “Holders”) and Olenox Industries Inc., a Delaware Corporation (the “Company”).

 

WHEREAS, as of the date hereof, the Holders collectively own all of the Series D Preferred Stock (the “Existing Preferred”) of the Company.

 

WHEREAS, the Holders desire to surrender the Existing Preferred in exchange for an equal number of shares of Series E Preferred Stock (the “New Preferred”) of the Company;

 

WHEREAS, the Company desires to accept the surrender of the Existing Preferred in exchange for the issuance of the New Preferred in accordance with the terms of this Agreement.

 

ACCORDINGLY, the parties agree as follows:

…

FOURTH AMENDMENT TO THE

FIRST CITIZENS COMMUNITY BANK

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

 

This Fourth Amendment (this “Amendment”) to the First Citizens Community Bank Supplemental Executive Retirement Plan, as amended (the “SERP”), is effective as of June 16, 2026.

 

W I T N E S S E T H:

 

WHEREAS, First Citizens Community Bank (the “Bank”) maintains the SERP for the benefit of certain senior officers; and

 

WHEREAS, the Board of Directors of the Bank resolved to amend the SERP to make certain modifications, effective as of June 16, 2026.

 

NOW, THEREFORE, the SERP is hereby amended as follows:

 

1. Appendix A to the SERP is deleted in its entirety, to be replaced by the Appendix A attached to this Amendment.

2. Appendix B to the SERP is deleted in its entirety, to be replaced by the Appendix B attached to this Amendment.

 

 

IN WITNESS WHEREOF, the Bank has caused this Amendment to be executed by its duly authorized officer on June 16, 2026.

 

 

By: Gina Marie Boor

Title: Corporate Secretary

Signature: /s/ Gina Marie Boor

…

---

Exhibit 10.2

LICENSE AGREEMENT

 

This License Agreement (“Agreement”) is entered into and effective as of June 17, 2026 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Paragon”), having its principal place of business at 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453, and Apogee Therapeutics, Inc. (“Apogee”), a corporation organized under the laws of the State of Delaware, having its principal place of business at 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453.  Paragon and Apogee are also referred to herein individually as a “Party”, or collectively as the “Parties.”

 

RECITALS

 

Whereas, Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets;

…

---

Exhibit 10.1

ANTIBODY DISCOVERY AGREEMENT

This Antibody Discovery Agreement (“Agreement”) is entered into and effective as of June 17, 2026 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), and Apogee Therapeutics, Inc., a Delaware corporation (“Apogee”).  Paragon and Apogee are also referred to herein individually as a “Party”, or collectively as the “Parties.”

Recitals

Whereas, Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets;

Whereas, Paragon has been performing and may continue to perform certain antibody discovery and development activities for Apogee to discover, generate, identify and characterize monospecific antibody candidates Directed To the Licensed Target, all on the terms and subject to the conditions set forth in this Agreement; and

…

WARNING: The following actions may trigger Austrian stamp duty:

 

(a)

this document is signed in Austria;

 

(b)

the original, or a certified copy, of this document or of a Substitute Document (as defined below) (all such documents being “Stamp Duty Sensitive Documents”) is brought into Austria (including by way of fax and email); and/or

 

(c)

a Substitute Document is created in Austria.

“Substitute Document” means any signed document in writing by a party to this document (including further agreements, letters, faxes or email) referencing a Stamp Duty Sensitive Document (including other Substitute Documents) or the transactions documented in such Stamp Duty Sensitive Document.

Contact the legal department / legal advisors prior to making a reference to this Amendment or the transactions documented therein (including fax or email and even if the written reference is only for personal purposes and not directed to third parties) and obtain confirmation, that no stamp duty will be incurred by such action.

CONSENT AND FOURTH AMENDMENT TO CREDIT AGREEMENT

…

Exhibit 10.1

 

EYEPOINT, INC.

AMENDMENT NO. 3 TO THE 2023 Long Term INCENTIVE PLAN

 

 

WHEREAS, EyePoint, Inc. (the “Company”) maintains the EyePoint, Inc. 2023 Long-Term Incentive Plan, originally effective as of June 20, 2023, as first amended as of June 20, 2024 and as further amended as of June 18, 2025 (as amended, the “Plan”);

 

WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee (“Compensation Committee”) of the Board of Directors of the Company (the “Board”) may amend the Plan at any time; provided that, amendments to the Plan must be approved by the Company’s stockholders if and to the extent required by applicable laws or stock exchange requirements (“Stockholder Approval”);

 

WHEREAS, the Compensation Committee, in consultation with legal and financial advisors, has determined that it is advisable and in the best interests of the Company and its stockholders to increase the number of shares of the Company’s common stock, $0.001 par value per share, reserved for issuance under the Plan by 4,900,000 shares (the “Share Increase”);

…

Exhibit 10.1 

 

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [*] INDICATES THAT INFORMATION HAS BEEN REDACTED.

 

EXYN TECHNOLOGIES, INC. CONFIDENTIAL SIDE LETTER AGREEMENT

 

Dated as of May 18, 2026

 

Evergreen Capital Management, LLC

 

Attention: Jeff Pazdro, Manager

 

[Address on file]

 

Re: Confidential Side Letter to the Second Amendment to Note and Warrant Purchase Agreement, dated as of May 8, 2026, between Exyn Technologies, Inc. and Evergreen Capital Management, LLC

 

Ladies and Gentlemen:

…

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase Agreement (this “Agreement”) is dated as of June 18, 2026, between CervoMed Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

 

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE I. DEFINITIONS

…

CONFIDENTIAL

 

Digital Asset Acquisition Corp.

 

FORM OF NON-REDEMPTION AGREEMENT

 

This NON-REDEMPTION AGREEMENT (this “Agreement”), dated as of [●], 2026, is made by and among Digital Asset Acquisition Corp., a Cayman Islands exempted company (as such entity exists on the date hereof and as it exists following the Domestication and the Merger as described below, as applicable, the “Company”), and the undersigned investor (the “Investor”).

 

WHEREAS, the Company is a special purpose acquisition company whose Class A ordinary shares (“Ordinary Shares”) are traded on the Nasdaq Stock Market LLC under the symbol “DAAQ”;

 

WHEREAS, on January 13, 2026, the Company entered into a business combination agreement (the “Business Combination Agreement”), by and between the Company and Old Glory Holding Company, a Delaware corporation, registered as a Bank Holding Company under the Bank Holding Company Act of 1956 (“Old Glory”);

…

THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED.

EXCHANGE AGREEMENT

This Exchange Agreement (this “Agreement”) is entered into as of June 18, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liablity company (“Lender”), and Jaguar Health, Inc., a Delaware corporation (“Borrower”). Capitalized terms used in this Agreement without definition shall have the meanings given to them in the Royalty Interest (as defined below).

A. Company previously sold and issued to Investor that certain Royalty Interest dated August 24, 2022 (the “Royalty Interest”) pursuant to that certain Royalty Interest Purchase Agreement dated August 24, 2022 (the “Purchase Agreement,” and together with the Royalty Interest and all other documents entered into in conjunction therewith, the “Transaction Documents”).

…